Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Mar 10, 2016
Catalent today announced that Dr. Gregory Bleck, Global Head of R&D, Catalent Biologics, will be presenting at the upcoming BioProcess International West Conference, to be held at the Oakland Marriott City Center Hotel, Oakland, CA, on March 14th – 17th, 2016.
Mar 1, 2016
Acticor Biotech today announced that it selected Catalent’s proprietary GPEx® technology for the development of its Fab candidate, ACT-017, targeting the platelet glycoprotein VI (GPVI).
Jan 28, 2016
Catalent Pharma Solutions today announced that Cerenis Therapeutics has advanced its leading clinical candidate, CER-001, into Phase III clinical studies across Europe and North America.
Jan 13, 2016
Catalent today announced, through its wholly-owned subsidiary, Redwood Bioscience, Inc., a research collaboration with Roche to develop next-generation molecules coupling different therapeutic modalities using Catalent’s proprietary SMARTag™ technology.
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
